Phase I Study to Determine the Safety of MS-209 [dofequidar] in Combination With Docetaxel in Patients With a Solid Progressive Tumor.
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2012
At a glance
- Drugs Docetaxel (Primary) ; Dofequidar (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Sep 2005 New trial record.